Association between macrocytosis and metachronous squamous cell carcinoma of the esophagus after endoscopic resection in men with early esophageal squamous cell carcinoma.
Adult
Aged
Endoscopy
/ adverse effects
Erythrocyte Indices
Erythrocytes, Abnormal
Esophageal Neoplasms
/ pathology
Esophageal Squamous Cell Carcinoma
/ surgery
Female
Follow-Up Studies
Hematologic Diseases
/ complications
Humans
Incidence
Male
Middle Aged
Neoplasms, Second Primary
/ epidemiology
Predictive Value of Tests
Proportional Hazards Models
Prospective Studies
Risk Factors
Endoscopic resection
Esophageal cancer
Macrocytosis
Mean corpuscular volume
Metachronous cancer
Journal
Esophagus : official journal of the Japan Esophageal Society
ISSN: 1612-9067
Titre abrégé: Esophagus
Pays: Japan
ID NLM: 101206627
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
13
09
2018
accepted:
03
07
2019
pubmed:
10
7
2019
medline:
15
7
2021
entrez:
9
7
2019
Statut:
ppublish
Résumé
Macrocytosis is associated with an increased risk of squamous cell carcinoma (SCC) arising in the esophagus in men. The aim of this study was to evaluate the association between macrocytosis and metachronous SCC of the esophagus after endoscopic resection (ER) of early esophageal SCC in men. The study group comprised 278 men with early esophageal SCC after ER. The main study variables were as follows: (1) cumulative incidence and total number of metachronous SCC of the esophagus according to the presence or absence of macrocytosis (mean corpuscular volume ≥ 106 fl) and (2) predictors of metachronous SCC of the esophagus as assessed with a multivariate Cox proportional-hazards model. The median follow-up was 50.3 months. Macrocytosis was associated with a higher 2-year cumulative incidence of metachronous SCC of the esophagus (without macrocytosis vs. with macrocytosis: 11.4% vs. 38.1%, p = 0.002). Macrocytosis was also associated with a higher total number of metachronous SCC of the esophagus per 100 person-years (without macrocytosis vs. with macrocytosis: 7.7 vs. 31.5 per 100 person-years, p < 0.0001). In addition, macrocytosis was a significant predictor of metachronous SCC of the esophagus on multivariate Cox proportional-hazards analysis (relative risk 2.23). Macrocytosis is a useful predictor of the risk of metachronous SCC of the esophagus after ER of early esophageal SCC in men.
Sections du résumé
BACKGROUND
Macrocytosis is associated with an increased risk of squamous cell carcinoma (SCC) arising in the esophagus in men. The aim of this study was to evaluate the association between macrocytosis and metachronous SCC of the esophagus after endoscopic resection (ER) of early esophageal SCC in men.
METHODS
The study group comprised 278 men with early esophageal SCC after ER. The main study variables were as follows: (1) cumulative incidence and total number of metachronous SCC of the esophagus according to the presence or absence of macrocytosis (mean corpuscular volume ≥ 106 fl) and (2) predictors of metachronous SCC of the esophagus as assessed with a multivariate Cox proportional-hazards model.
RESULTS
The median follow-up was 50.3 months. Macrocytosis was associated with a higher 2-year cumulative incidence of metachronous SCC of the esophagus (without macrocytosis vs. with macrocytosis: 11.4% vs. 38.1%, p = 0.002). Macrocytosis was also associated with a higher total number of metachronous SCC of the esophagus per 100 person-years (without macrocytosis vs. with macrocytosis: 7.7 vs. 31.5 per 100 person-years, p < 0.0001). In addition, macrocytosis was a significant predictor of metachronous SCC of the esophagus on multivariate Cox proportional-hazards analysis (relative risk 2.23).
CONCLUSION
Macrocytosis is a useful predictor of the risk of metachronous SCC of the esophagus after ER of early esophageal SCC in men.
Identifiants
pubmed: 31281950
doi: 10.1007/s10388-019-00685-w
pii: 10.1007/s10388-019-00685-w
doi:
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-158Subventions
Organisme : National Cancer Center (NCC) Research and Development Fund
ID : 36
Pays : International
Références
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2209-15
pubmed: 17119048
Laryngoscope. 2012 Jun;122(6):1291-6
pubmed: 22674532
Gastrointest Endosc. 2002 Oct;56(4):517-21
pubmed: 12297767
Helicobacter. 2014 Jun;19(3):194-201
pubmed: 24612125
Alcohol Clin Exp Res. 1991 Oct;15(5):871-6
pubmed: 1755522
Am J Gastroenterol. 2011 May;106(5):858-66
pubmed: 21468010
Cancer Prev Res (Phila). 2011 Dec;4(12):1982-92
pubmed: 21952583
Lancet Oncol. 2009 Nov;10(11):1033-4
pubmed: 19891056
Alcohol Clin Exp Res. 2014 May;38(5):1237-46
pubmed: 24588059
J Clin Oncol. 2003 Dec 1;21(23):4336-41
pubmed: 14645422
Alcohol Clin Exp Res. 2003 Sep;27(9):1395-401
pubmed: 14506399
Gut. 2000 Aug;47(2):256-61
pubmed: 10896918
Alcohol Clin Exp Res. 2000 Apr;24(4 Suppl):30S-33S
pubmed: 10803776
Int J Cancer. 2012 Jun 15;130(12):2949-60
pubmed: 21796615
Endoscopy. 2009 Apr;41(4):304-9
pubmed: 19340732
Endoscopy. 2003 Apr;35(4):322-6
pubmed: 12664389
J Gastroenterol Hepatol. 2015 Jan;30(1):75-81
pubmed: 25088761
Dis Esophagus. 2014 Jul;27(5):457-62
pubmed: 23009284
Gastroenterology. 2016 Nov;151(5):860-869.e7
pubmed: 27492616
Lancet. 1974 May 4;1(7862):829-31
pubmed: 4132788
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
Dig Endosc. 2013 Mar;25 Suppl 1:39-43
pubmed: 23480401
Blood. 2002 May 1;99(9):3487-8
pubmed: 12001910
Gut. 2008 Sep;57(9):1200-6
pubmed: 18460553
Br J Haematol. 1979 Dec;43(4):631-6
pubmed: 526445
Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1227-33
pubmed: 14652286
Carcinogenesis. 2003 Nov;24(11):1773-8
pubmed: 12949054
Aliment Pharmacol Ther. 2014 Mar;39(6):609-18
pubmed: 24461252